Liquidia Technologies Inc (LQDA) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.
Total Assets Chart for Liquidia Technologies Inc
Liquidia Technologies Inc (LQDA) total assets for FY2025 were USD 327.9M, a 42.4% change from FY2024. Liquidia Technologies Inc's total assets grew from USD 8.5M in 2016 to USD 327.9M in 2025 (3764.2% over 9 years). Total assets compound annual growth rate: 5-year CAGR of 26.9%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $3.82B
- Implied Share Price
- $42.65
- Enterprise Value
- $5.97B
- Revenue (TTM)
- $450.91M
- EBITDA
- $169.77M
- Profit Margin
- 30.74%
- Trailing P/E
- 30.68
- Forward P/E
- 10.58
- Price/Book (MRQ)
- 31.12
- Price/Sales (TTM)
- 8.47
- EV/EBITDA
- 33.58
- EV/Revenue
- 13.24
- Dividend Yield
- —
- Book Value
- $2.19
- Free Cash Flow (FY2025)
- -$40.02M
- Free Cash Flow Yield
- -1.05%
Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.